New Delhi: The expert panel of Drug Controller General of India (DCGI) on Thursday recommended that emergency use authorization be granted to the COVID-19 vaccine Corbevax for children in the age group of 5 to 12 years.
Corbevax, developed by Hyderabad-based firm Biological-E, is India’s first indigenously-developed RBD protein sub-unit vaccine against the coronavirus.
It is being administered to children in the age group of 12 to 14 from March 16, 2022.
Meanwhile, the government panel has sought more data from Bharat Biotech before granting emergency use approval to Covaxin among children aged 5-12.
The 5-12 age group is yet to brought under the nationwide inoculation drive.
Kolkata: With emotions running high well before Indian and Pakistan clash for Champions Trophy in… Read More
Bhubaneswar: The India Meteorological Department (IMD) has issued nowcast warning for six districts of Odisha… Read More
Bhubaneswar: Excitement is reaching fever pitch as millions of fans from India and Pakistan tune… Read More
New Delhi: In the 119th episode of his monthly radio program "Mann Ki Baat," broadcast… Read More
New Delhi: Italian Prime Minister Giorgia Meloni has recently expressed strong support for global conservative… Read More
New Delhi: The Indian cricket team will take on arch-rivals Pakistan in their second Group… Read More
This website uses cookies.
